Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer ...

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses current efforts in increasing biosimilar adoption and pharmacy benefit manager (PBM) reform.

Elizabeth Grush, MBA, speaks to the support, benefits, and holistic considerations that patient-centered care can provide for the betterment of patient experiences and outcomes.

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

Raj Chovatiya, MD, PhD, MSCI, highlights the long-term effectiveness of lebrikizumab across diverse patients, including those with prior biologic use, positioning it as a potential first-line ...

While findings around hospital and emergency department use were similar at the individual and neighborhood levels, the use of outpatient services differed.

The electronic health record (EHR)–based symptom inventory identified symptom prevalence and associated comorbidities, but no ovarian cancers were diagnosed during the study period.

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing ...

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for ...

A recent review highlights the gaps in clinical guidelines and treatment approaches for metabolic dysfunction-associated steatohepatitis (MASH) and looks ahead to the future promise of glucagon-like ...

An expert discusses how the VISIBLE study examined comorbidity burden in moderate to severe psoriasis across all skin tones, addressing disparities in research. It aimed to highlight unmet needs and ...